Roche Diabetes Care Sharpens Focus on Indian Market
Accu-Chek Active Blood Glucose Monitoring Meters now Made in India
- Improve access to diabetes care by shortening time-to-market
- Become sustainable by reducing carbon footprint
Mumbai, India, 04 May 2023: Roche Diabetes Care India (RDC India) today announced that their blood glucose monitoring device ‘Accu-Chek Active’ is now manufactured in India. This move is a part of the company's strategy to improve access to diabetes care and meet the growing needs of the Indian market in collaboration with their manufacturing partner Sanmina-SCI India Pvt. Ltd. and assembly & distribution partner Parekh Integrated Services Pvt. Ltd. (PISPL).
The production of Accu-Chek Active meters will take place in Sanmina’s state-of-the-art multi-client manufacturing site in Chennai, India, in line with the globally approved quality standards synonymous with the brand.
The new Accu-Chek Active product packs will now proudly display the ‘Made in India’ tag. With the decision to manufacture these products in India, RDC India aims to make Accu-Chek Active to reduce the time to market thus making Accu-Chek Active meters more accessible to the growing number of people with diabetes in the country. At the same time this move will also help RDC India contribute to the global sustainability goals of reducing their carbon footprint versus imports.
Speaking about this launch, Omar Sherief Mohammad, Cluster Head – India Middle East and Africa, RDC said, "We are delighted to announce the manufacturing of Accu-Chek Active meters in India in partnership with Sanmina. For 125 years, sustainability has been an integral part of Roche’s business. This move is in line with our commitment to improve access to diabetes care by shortening our time to market and become more sustainable in our operations by reducing our carbon footprint.
We are confident that this strategic decision will help us strengthen our position as a leader in the blood glucose monitoring market in India. ”
Speaking on the occasion, Mike Landy, President and COO Integrated Manufacturing Services of Sanmina said, “Sanmina has had a long-standing presence in India for over 20 years. Today Sanmina provides end to end services including, product design, advanced technologies, manufacturing, and logistics solutions from our 100-acre campus to companies that have mission critical applications and products, like Roche. We are proud to be the manufacturing partner of Roche Diabetes Care India and are honored that the products we are manufacturing will have a significant impact in diabetes care and wellness for the people of India.”
Speaking on the occasion, Mr. Vikram H Parekh, Chairman and Director, PISPL said, “We are proud to be a strategic partner to Roche Diabetes Care India in their aim to improve access to diabetes care in India. We have been associated with the brand for the past two decades, providing kitting, warehousing and distribution solutions for their Accu-Chek Active meters at our Bhiwandi location in Maharashtra. Our warehouse at Bhiwandi is fully sustainable having received the Green Warehouse Interior Fit-out certification by the Indian Green Building Council (GBC) in November 2022. We are committed to supporting Roche in their purpose of improving access to diabetes care through innovation.”
Roche Diabetes Care India offers integrated personalised diabetes management (iPDM) products and solutions through their Accu-Chek range of blood glucose monitoring systems including Accu-Chek Active, Accu-Chek Guide, Accu-Chek Instant and Accu-Chek Instant S as well as tech-driven solutions on their mobile application mySugr. The Accu-Chek blood glucose monitoring meters have been trusted by millions of people with diabetes in India and worldwide for over four decades.
The first batch of Accu-Chek Active meters manufactured in India are already available in the market across the country.
About Roche Diabetes Care
Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 4,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.
Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualising relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief.
Since 2017, mySugr, one of the most popular diabetes management apps, is part of Roche Diabetes Care.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For more information please contact:
Cluster Communications Lead
Roche Diabetes Care India, Middle East & Africa
Email: [email protected]